Company Insights

VNRX customer relationships

Explore interactive graphBrowse insights index

VNRX customers relationship map

VolitionRx (VNRX): Commercial traction through licensing, lab partnerships and distributor networks

VolitionRx develops blood-based epigenetic assays (Nu.Q®) for human and veterinary oncology and monetizes through a mix of licensing deals, supply agreements, distributor sales, and laboratory service revenues. The company captures near-term cash via upfront and milestone licensing payments while expanding addressable markets through reseller and central-lab partners that perform or distribute the Nu.Q tests across EMEA, APAC and North America. For investors, the model is asset-light on go-to-market but dependent on a small set of large partners and milestone-driven licensing cashflows. Learn more at the NullExposure homepage.

How VolitionRx actually makes money and how that shapes operating risk

VolitionRx’s revenue profile combines three monetization levers: upfront and milestone license receipts, supply and manufacturing revenues tied to license/supply agreements, and lab/distributor channel sales for both human and veterinary tests. Company disclosures show a significant licensing cash injection: Volition recorded a $10.0 million upfront in Q1 2022 and further upfronts totalled $13.0 million in Q4 2023, with a total $28.0 million of milestone consideration expected to be recognized over time — a clear signal that licensing is a core monetization driver. This structure imposes specific operating characteristics:

  • Contracting posture: the company pursues licensing plus supply arrangements that blend intellectual property monetization with ongoing manufacturing commitments. The Heska license cited in filings exemplifies this dual nature where the license and supply obligations are treated as a combined performance obligation.
  • Concentration: sales concentration is material — sales to the three largest customers comprised over 67% of 2024 revenues, creating exposure to partner-specific demand and contract renewal risk.
  • Criticality and dependency: Volition controls specialized components and manufacturing for certain partners; supply services are described as highly specialized and dependent on the Company, making partner relationships operationally critical.
  • Geographic rollout and maturity: the go-to-market is global in intent — Nu.Q Vet and human assays are distributed across NA, EMEA and APAC, and many partnerships are in active commercialization or validation phases, indicating a transition from R&D to early commercial maturity.

These operational constraints explain why Volition pursues multiple partner types (distributors, central labs, co-marketing partners) rather than building a fully owned salesforce.

Commercial counterparties: the partner map investors should know

Below I cover every customer/partner relationship disclosed in public reporting and transcripts in the sample set. Each entry is a 1–2 sentence plain-English summary with the cited source.

  • Medical & Biological Laboratories Co. Ltd (MBL) — Volition appointed MBL as a non-exclusive distributor for Nu.Q® Discover assays in Japan to widen market access. Source: company announcement reported on StockTitan (Mar 10, 2026) and corroborated in Investing.com (May 4, 2026).

  • Hospices Civils de Lyon (HCL) — HCL purchased Nu.Q Cancer assays and is supporting a reimbursement dossier and clinical certification efforts to introduce the test into reimbursed clinical practice in France. Source: Volition commentary and press coverage via InsiderMonkey (Q4 2025 earnings call transcript, cited May 4, 2026) and Yahoo Finance press release coverage (Mar 10, 2026).

  • Hologic (HOLX) — Volition signed a co‑marketing and service agreement with Hologic, initiating implementation of the human licensing strategy and co-marketing Nu.Q Discover. Source: Q3/Q4 2025 earnings call transcripts as reported by InsiderMonkey (Mar–May 2026).

  • Bioguard — Bioguard was appointed to provide the Nu.Q Vet Cancer test in Taiwan and China, expanding Volition’s Asia lab footprint for veterinary assays. Source: Investing.com reporting on the company’s filings (May 4, 2026).

  • Midwest Veterinary Laboratory — Midwest Veterinary Laboratory will offer the Nu.Q Vet Cancer test across all 50 U.S. states starting in 2026, expanding U.S. veterinary access. Source: Investing.com coverage of company filings (May 4, 2026).

  • Fujifilm Vet Systems / Fujifilm Vet Systems Co. Ltd — Fujifilm Vet Systems expanded a contract to validate and implement a centralized automated platform (IDS-i10 analyzer) and has a supply agreement enabling the sale and performance of Nu.Q® Vet Cancer Test across its Japanese central lab network. Source: InsiderMonkey Q3 2025 earnings call transcript and StockTitan press coverage (Mar 2026).

  • Werfen — Volition granted Werfen a research license and an exclusive commercial option for antiphospholipid syndrome (APS), and Werfen will investigate the clinical utility of Volition’s Nu.Q H3.1 NETs assay on its platforms. Source: Q3 2025 earnings call transcript and subsequent Q4 commentary reported by InsiderMonkey (Mar–May 2026).

  • Revvity (RVTY) — Revvity is selling Volition’s assays in Europe and analyzing multiple use-cases beyond APS, advancing validation and commercial testing for expanded indications. Source: Q3 2025 earnings call transcript reported via InsiderMonkey (Mar 2026).

  • Lind Global Asset Management XII — Volition entered an amended securities purchase agreement with Lind Global Asset Management XII to secure $2.0 million in funding, a capital provider relationship rather than a commercial customer. Source: TradingView news item summarizing the agreement (Mar 10, 2026).

  • Revvity (RVTY) — duplicate listing — (covered above) Source: InsiderMonkey (Q3 2025).

  • IDEXX — IDEXX is listed among leading industry players with supply agreements instrumental to veterinary market reach; this relationship supports distribution and laboratory-based sales. Source: Q3 2025 earnings call transcript cited on InsiderMonkey (Mar 2026).

  • Antech (part of Mars Science and Diagnostics) — Antech is named as a supply/distribution partner supporting veterinary adoption via established channel networks. Source: Q3 2025 earnings call transcript reported on InsiderMonkey (Mar 2026).

  • Heska (referenced in company filings) — Although not present in the relationship results list, company filings explicitly detail a Master License and Supply Agreement with Heska that granted worldwide exclusive POC rights and non-exclusive kit rights, included upfront consideration and represents a material licensing/supply contract. This is a company-level license example cited in Volition’s filings (2022–2023) and underpins several constraints discussed below.

Operating implications and investor takeaways

  • Revenue is milestone- and partner-driven. The $28.0 million figure of total milestone consideration (with $23.0 million deferred revenue at one point) demonstrates reliance on licensing cashflows rather than purely recurring test sales. This produces lumpy revenue recognition tied to partner activity.
  • Concentration risk is meaningful. With over 67% of 2024 sales coming from the top three customers, Volition’s near-term results depend heavily on a handful of commercial relationships.
  • Geographic reach is broad but partner-dependent. The company executes market entry through distributors and central labs across NA, EMEA and APAC, favoring rapid reach over direct salesforce investment.
  • Operational criticality of manufacturing. Where licenses include supply services (Heska example), Volition remains essential to product delivery, creating both negotiating leverage and operational exposure if capacity or quality issues arise.

For deeper relationship intelligence and monitoring of partner milestones, see the NullExposure homepage.

Bottom line for investors

VolitionRx is transitioning from an R&D profile to a commercial licensing and partner-driven business. Strengths: diversified partner types, meaningful licensing cash inflows, and global channel coverage. Risks: high customer concentration, dependency on a few large partners for near-term revenue, and execution-sensitive supply obligations. Investors should watch milestone recognition, the pace of lab rollouts (Midwest Vet, Bioguard, Fujifilm, IDEXX), and co‑marketing implementations (Hologic, Revvity) as the principal drivers of revenue inflection over the next 12–24 months.

Join our Discord